Researchers Identify PIKfyve as Hepatitis E Target
A new study reveals that targeting the PIKfyve enzyme with apilimod may significantly inhibit hepatitis E viral infection.
Updated on Oct. 29, 2026 in Life Sciences
Live Poll
Should researchers prioritize repurposing existing drugs to treat new viral infections?
Scientists at Jilin University have identified the host enzyme PIKfyve as a critical target for inhibiting the hepatitis E virus. Laboratory models demonstrate that the compound apilimod effectively reduces viral infection by disrupting the endolysosomal transport required for viral entry.
Why it matters
Current treatments for hepatitis E rely on ribavirin, which is frequently associated with toxicity and significant contraindications. Developing targeted alternatives like apilimod could provide safer, more effective therapeutic options for patients battling the virus.
Silencing the PIKfyve enzyme results in a 40% reduction in hepatitis E infection, while rats treated with 75 mg/kg of apilimod for 12 days showed inhibited viral activity. Future clinical development must still establish human dosage and safety parameters.
The players
Jilin University
This is a public research university located in Changchun, Jilin, China, where the study on hepatitis E inhibitors was conducted.
The details
The research highlights that PIKfyve inhibition effectively blocks the viral uncoating process by reducing the maturation of cathepsins B and L. Beyond apilimod, other compounds such as raloxifene, verapamil, chloroquine, and tamoxifen were also found to inhibit viral infection in a dose-dependent manner.
Timeline
October 29, 2026: The research article detailing these findings was published.
The Big Picture
This study marks a potential departure from the standard reliance on ribavirin for treating hepatitis E. By targeting the host enzyme PIKfyve, researchers are moving away from traditional antiviral mechanisms toward therapies that specifically disrupt viral endolysosomal transport.
While these findings are limited to laboratory and animal models, they suggest a future path toward new hepatitis E medications with fewer side effects than current standards. Patients should continue following existing treatment protocols until further clinical trials confirm safety in humans.
The takeaway
Targeting host proteins rather than the virus itself offers a promising strategy to overcome limitations like drug toxicity. Continued research will focus on whether these inhibitors can be safely adapted for human therapeutic use.
Further reading
For more information on ongoing clinical breakthroughs, visit our Life Sciences section.
More information
View the complete peer-reviewed research article for detailed methodology and data.
Source note: This article includes information reported by News-Medical.
Live Poll
Should researchers prioritize repurposing existing drugs to treat new viral infections?
